Research Advancing to Market Production for Innovators Act
- Bill Number
- S. 1660
- Origin Chamber
- Senate
- Congress
- 119th Congress, Session 1
- Policy Area
- Commerce
- Status
- Introduced
- Latest Action
- 2025-05-07: Read twice and referred to the Committee on Small Business and Entrepreneurship.
- Last Updated
- 2025-12-05T21:47:59Z
AI-Generated Summary
Purpose
The "Research Advancing to Market Production for Innovators Act" (RAMP for Innovators Act) aims to enhance the commercialization of technologies developed through the Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs. These programs fund small businesses for research and development (R&D) projects with potential federal applications. The bill seeks to streamline processes, provide better support for turning innovations into marketable products, and improve tracking of program outcomes to boost economic growth and innovation.
Key Provisions
- Peer Review Enhancements: Requires SBIR and STTR peer reviews to evaluate commercialization potential alongside scientific merit and feasibility, including at least one expert reviewer on commercialization.
- Phase Flexibility Expansion: Allows all federal agencies with SBIR/STTR programs to provide flexible funding phases for fiscal years 2025–2027, limited to 10% of total program funds (15% for the National Institutes of Health). Includes a required briefing to Congress on this authority.
- Technology Commercialization Official: Mandates each participating federal agency to designate an official (or identify an existing one) to guide awardees on commercialization, identify promising technologies for further contracts, coordinate across agencies, and report annually on progress.
- Technical and Business Assistance Improvements: Authorizes award recipients to choose and use assistance for services like intellectual property protection, cybersecurity, and staff training. Increases funding limits: up to $6,500 for Phase I awards and $50,000 for Phase II awards, with flexible sourcing options. Allows targeted agency reviews of assistance usage.
- I-Corps Participation: Requires agencies with I-Corps (Innovation Corps) programs to offer participation options to SBIR/STTR recipients, funding it through grants, assistance awards, or other sources.
- Commercialization Impact Assessment: Directs the Small Business Administration (SBA) to coordinate annual reports assessing outcomes for companies with 50+ Phase II awards over the prior 9 years, covering metrics like revenues, investments, patents, mergers, and employment. These reports must be published and submitted to congressional committees.
- Patent Assistance: Establishes an interagency agreement with the U.S. Patent and Trademark Office (USPTO) for prioritized patent examinations for SBIR/STTR recipients and outreach on pro se (self-represented) assistance and scam prevention.
Significant Changes to Existing Law
- Shortened Timelines: Reduces the review period for certain SBIR/STTR processes from 1 year to 180 days.
- Broadened Eligibility and Flexibility: Extends phase flexibility beyond specific agencies (e.g., NIH, DoD, Education) to all SBIR/STTR agencies and adds funding caps. Previously limited to fiscal years 2012–2025; now specified for 2025–2027 with new limits.
- Mandatory Assistance and Roles: Shifts from optional vendor agreements to required authorization for recipient-chosen assistance, adds cybersecurity and staff hiring provisions, and increases per-project funding caps (previously lower or unspecified).
- New Reporting and Support Mechanisms: Introduces the Technology Commercialization Official role, annual impact assessments with detailed metrics, I-Corps integration, and USPTO patent prioritization—none of which existed before.
- Review Process Updates: Mandates commercialization focus in peer reviews and allows targeted audits of assistance funds.
Potential Impacts
- On Government Agencies: Increases administrative burdens for designating officials, conducting reviews, and reporting, but could lead to more efficient technology transitions to federal contracts (Phase III). May enhance interagency coordination and data collection for better program evaluation.
- On Citizens and Businesses: Small businesses, especially innovators in tech and R&D, gain easier access to commercialization support, funding for patents and training, and market pathways, potentially accelerating job creation and economic growth. Could reduce barriers for underrepresented entrepreneurs.
- On International Relations: Minimal direct impact, though improved U.S. innovation commercialization might strengthen global competitiveness in technology sectors like defense and health.
Main Stakeholders Affected
- Small Businesses: Primary beneficiaries as SBIR/STTR award recipients, gaining enhanced support for turning R&D into products.
- Federal Agencies: Including SBA, NIH, DoD, and others with SBIR/STTR programs; required to implement new roles, reviews, and reporting.
- Congressional Committees: Senate Small Business and Entrepreneurship, House Small Business, and House Science, Space, and Technology; receive briefings and reports for oversight.
- USPTO and SBA: Collaborate on patent assistance and outreach.
- Vendors and Experts: Providers of technical/business services, including commercialization specialists.
Notable Legal, Constitutional, or Political Implications
- Legal: Amends the Small Business Act (15 U.S.C. 638) without altering core constitutional frameworks; ensures compliance with existing federal funding rules by capping flexible awards. The interagency patent agreement reinforces intellectual property protections under U.S. law.
- Constitutional: No direct challenges; supports Article I's commerce clause by promoting interstate economic activity through innovation.
- Political: Bipartisan introduction (Sens. Coons and Curtis) signals broad support for small business innovation. Could influence future appropriations for SBIR/STTR (totaling billions annually) and highlight tensions between program expansion and fiscal limits. Annual assessments may inform debates on program effectiveness and equity in federal R&D spending.
This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.
Sponsor
Sen. Coons, Christopher A. [D-DE]
Cosponsors (1)
Recent Actions
- 2025-05-07: Read twice and referred to the Committee on Small Business and Entrepreneurship.
- 2025-05-07: Introduced in Senate
Bill Versions
- Research Advancing to Market Production for Innovators Act — issued 2025-05-07 — PDF (13 pages)